Current landscape of long COVID clinical trials

Manojit Bhattacharya, Srijan Chatterjee, Sanskriti Saxena,Shyam Sundar Nandi, Sang-Soo Lee,Chiranjib Chakraborty

International Immunopharmacology(2024)

引用 0|浏览0
暂无评分
摘要
Long COVID was reported as a multi-systemic condition after the infection of SARS-CoV-2, and more than 65 million people are suffering from this disease. It has been noted that around 10% of severe SARS-CoV-2 infected individuals are suffering from the enduring effects of long COVID. The symptoms of long COVID have also been noted in several mild or asymptomatic SARS-CoV-2 infected individuals. While limited reports on clinical trials investigating new therapeutics for long COVID exist, there is an abundance of scattered information available regarding these trials. This review explores the extensive literature search, and complete clinical trial database search to map the current status of long COVID clinical trials worldwide. The study listed about 110 long COVID clinical trials. In addition to conducting extensive long COVID clinical trials, we have comprehensively presented an overview of the condition, its symptoms, notable manifestations, associated clinical trials, the unique challenges it poses, and our recommendations for addressing long COVID.
更多
查看译文
关键词
SARS-CoV-2,Long COVID,PASC (post-acute sequelae of COVID-19),Treatment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要